Moteur de recherche d’entreprises européennes
Financement de l’UE (2 863 734 €) : IMAGERIE ET TRAITEMENT ENDOSCOPIQUES MULTIMODES NON LINÉAIRES À BASE DE FIBRES Hor01/11/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
IMAGERIE ET TRAITEMENT ENDOSCOPIQUES MULTIMODES NON LINÉAIRES À BASE DE FIBRES
"MULTISCOPE introduces a revolutionary photonic technology that represents a significant advancement in the field of optical diagnostics and therapy. Our approach is based on cutting-edge research into pulse propagation within nonlinear complex structures. We are developing an endoscopic device that seamlessly combines optical biopsy and cold atmospheric plasma treatment. This dual-functionality device harnesses the spatiotemporal control of powerful light in multimode fibers, which were previously overlooked due to concerns about excessive light destructuring. We leverage the remarkable progress in the development of the latest optical fibers and in the precise control of light within multimode guides, enabling us to harness the power of plasma, the fourth state of matter. Initially, our focus is on gastrointestinal (GI) endoscopy, but our ultimate goal is to extend this technology to all areas of medical diagnostics where there is a pressing need for reliable tools for ""optical biopsy"" and ""instant pathology."" These tools are crucial for real-time diagnosis but have not yet reached the level of trustworthiness required for widespread use. Endoscopy is a vital tool for diagnosing and treating GI disorders, offering a safe and effective approach. However, the current standard of care still relies on histopathology for conclusive cancer diagnosis. This leads to significant delays in initiating treatment and incurs high costs. Our project is set to transform this landscape by bringing to life the long-anticipated concept of real-time, in-vivo optical diagnosis, often referred to as ""optical biopsy"". Our groundbreaking approach seamlessly integrates endoscopic capabilities with cold atmospheric plasma therapy, which employs controlled plasma jets to precisely target and eliminate cancer cells by inducing cellular apoptosis. By combining plasma therapy with optical biopsy, we not only provide real-time diagnosis but also offer immediate therapeutic intervention."
| Centre National de la Recherche Scientifique CNRS | 0,00 € |
| Erbe Elektromedizin GmbH | 378 935 € |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs | 589 375 € |
| Universita Cattolica Del Sacro Cuore | 546 875 € |
| Universita Degli Studi Di Roma LA Sapienza | 618 750 € |
| Universite de Limoges | 729 799 € |
https://cordis.europa.eu/project/id/101185664
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
